Stray Dog

BofA cuts HIMS 2026 GLP-1 revenue forecast to $516 million

  • Bad news: BofA cut its 2026 GLP-1 revenue forecast from $577 million to $516 million, revenue lost in the switch to branded drugs.
  • Bad news: Q1 consensus EPS is $0.05, down 75% year on year, as branded GLP-1 margins are far below the compounding era.
  • Good news: BofA's model has no peptide revenue, so a positive FDA advisory committee signal in July would be pure upside.
Read the full notes

BofA model detail

Allen Lutz

2026 GLP-1 revenue revision

Cut from $577 million to $516 million (revenue lost in the switch to branded drugs)

Peptide blind spot

The model includes no peptide revenue at all. A positive signal from the FDA advisory committee in July would be pure upside to the valuation.

PT

$21

Rating

Neutral

Management framework shift

Change

At its Q4 results, management chose to drop legacy metrics such as 'online revenue per user'

Interpretation

Management has a clear view of what the next strategic phase looks like

MerlinTrader view

'HIMS is no longer a single-product bet but a scaled consumer health engine that has been forced to mature faster'

New framing

An 'integrated revenue platform' (across channels, regions and care models)

Price action

17 Apr close

$28.67

18 Apr

Market closed for Good Friday

Q1 earnings

Consensus EPS

$0.05 (-75% YoY)

Consensus revenue

$619 million (+5.6% YoY)

Date

11 May, after the close

Reason for EPS decline

Branded GLP-1 margins are far below those of the compounding era

Key watchpoints
  • How many GLP-1 users convert to branded drugs (BofA expects 40-50%)
  • Progress on integrating Eucalyptus (90% of its revenue comes from distributing branded GLP-1s, and it is expected to cut EBITDA margin by 1-2 percentage points)
  • New subscriber growth (only +2% QoQ in Q4, currently the biggest worry)
  • Early guidance on Labs and peptides

Sources 3

  1. MerlinTrader in-depth report
  2. Benzinga
  3. BofA research